PERFIL SOROLÓGICO EXPERIMENTAL DE CAMUNDONGOS INFECTADOS COM A CEPA CISTOGÊNICA ME-49, DE Toxoplasma gondii ANTES E PÓSTERAPÊUTICA ESPECIFICA.

• Ano de defesa: 2008
• Autor(a) principal: GUIMARÃES, Liliane Rego
• Orientador(a): CASTRO, Ana Maria de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Goiás
• Programa de Pós-Graduação: Mestrado em Medicina Tropical
• Departamento: Medicina
• País: BR
• Palavras-chave em Português: Toxoplasma gondii; Tratamento; cepa cistogênica; ME-49; 1. Toxoplasma gondii 2. Toxoplasmose - Tratamento 3. Cepa cistogênica ME-49
• Palavras-chave em Inglês: Toxoplasma gondii; Treatment; ME-49; cystogenic lineage
• Área do conhecimento CNPq: CNPQ::CIENCIAS BIOLOGICAS::PARASITOLOGIA
• Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tde/1839

Toxoplasmosis is a protozoosis of high incidence in the world, caused by Toxoplasma gondii, transmitted by the ingestion of food contaminated by oocysts found in feline feces, or cists in raw or underdone meat, congenitally in other instances. The disease is usually asymptomatic, but in embryos or in imunodrepessive patients it may be devastating. In this work, the experimental serologic profile has been evaluated after specific therapy in isogenies mice Balbc, infected with a cystogenic lineage ME-49 of T. gondii. Fifty animals have been intra-peritoneal inoculated with 10 cists of T. gondii (lineage ME-49) obtained from the maceration of mice brains of previously inoculated mice. The mice have been divided into three groups of 15 animals each and a negative control group (not infected and not treated) of 5 animals. All the animals have been daily accompanied, and the symptoms were verified during 20 days. After this period, two groups of 15 animals underwent specific therapy schemes in which; group A: pirimetamin (12,5mg/kg/day) + folic acid; group B: pirimetamin + folic acid + sulfadiazine (500mg/kg/day), orally administrated during 10 consecutive days. After this period, all animals have been scarified, with an interval of 5 days, and the blood has been collected by a heart puncture and the serum separated for the Indirect Immuno-fluorescence Reaction. The samples from the treated animals presented a significant diminution in the quantity of (IgG) antibodies evaluated by the two schemes by the indirect immuno-fluorescence reaction (t=3,5, and t=7,6 respectively), in relation to the control group. There have been no significant differences between the two therapeutic schemes (t=0,36). Our results have shown that the experimental precocious treatment reduces significantly the IgG levels, suggesting a diminution of antigenic stimulus, and consequently a better prognosis for toxoplasmosis.